Ryan Fischesser - Sep 27, 2024 Form 3 Insider Report for Caribou Biosciences, Inc. (CRBU)

Role
VP of Finance and Controller
Signature
/s/ Barbara G. McClung, as attorney-in-fact
Stock symbol
CRBU
Transactions as of
Sep 27, 2024
Transactions value $
$0
Form type
3
Date filed
10/4/2024, 04:02 PM
Previous filing
Oct 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CRBU Common Stock 93.9K Sep 27, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CRBU Option to purchase Common Stock Sep 27, 2024 Common Stock 13.1K $4.11 Direct F2
holding CRBU Option to purchase Common Stock Sep 27, 2024 Common Stock 40K $15.16 Direct F3
holding CRBU Option to purchase Common Stock Sep 27, 2024 Common Stock 48K $6.12 Direct F4
holding CRBU Option to purchase Common Stock Sep 27, 2024 Common Stock 36K $6.81 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents: (i) 70,454 shares of Common Stock, par value $0.0001 per share ("Common Stock"), of Caribou Biosciences, Inc. (the "Issuer") beneficially owned by the reporting person, and (ii) 23,400 Restricted Stock Units ("RSUs") that will vest in four equal annual installments beginning on February 20, 2025 and that are settleable in shares of Common Stock within 30 days after each vesting date, subject to the reporting person's continued services to the Issuer through the applicable vesting dates.
F2 1/4th of the 27,270 shares originally subject to this option vested on January 1, 2022 and an additional 1/48th of the aggregate number of shares originally subject to the option vest on the corresponding day of each month thereafter until the option is fully vested on January 1, 2025, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.
F3 The shares subject to this option vest in equal monthly installments starting on January 20, 2022, the first monthly anniversary of the grant date, until the option is fully vested on December 20, 2025, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.
F4 The shares subject to this option vest in equal monthly installments starting on March 21, 2023, the first monthly anniversary of the grant date, until the option is fully vested on February 21, 2027, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.
F5 25% of the shares subject to this option will vest upon February 20, 2025, the one-year anniversary of the grant date, and 1/48th will vest monthly over the 36-month period thereafter, until the option is fully vested on February 20, 2028, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.

Remarks:

Exhibit 24 - Power of Attorney